Braunschweig, December 04, 2020 – YUMAB spin-off CORAT Therapeutics is developing a human antibody for the treatment of COVID-19 patients. Today, the company published the structure of this antibody and the history of its development, performed in the laboratories of Prof. Michael Hust and Prof. Stefan Duebel of the Technical University of Braunschweig in collaboration with YUMAB.
Dr. Thomas Schirrmann, CEO
Phone: +49-531 481170-0
CORAT Therapeutics GmbH
Dr. Andreas Herrmann, Managing Director
Phone: +49-152 2404 7488